PSTV
Plus Therapeutics, Inc.
Biotechnology
Market Cap$15M
5Y Perf.-99.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PSTV vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$84M
5Y Perf.-97.2%
PSTV vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PSTV | NRXP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $15M | $84M |
| Revenue (TTM) | $5M | $242K |
| Net Income (TTM) | $-22M | $-38M |
| Gross Margin | 91.5% | 59.5% |
| Operating Margin | -293.5% | -63.0% |
| Total Debt | $821K | $631K |
| Cash & Equiv. | $9M | $8M |
PSTV vs NRXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PSTV
NRXP
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Plus Therapeutics, … (PSTV) | 100 | 1.0 | -99.0% |
| NRx Pharmaceuticals… (NRXP) | 100 | 2.8 | -97.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PSTV vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PSTV leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. NRx Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PSTV
Plus Therapeutics, Inc.
The Income Pick
PSTV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.82
- Rev growth -10.5%, EPS growth 100.0%, 3Y rev CAGR 185.5%
- Lower volatility, beta 1.82, Low D/E 20.5%, current ratio 1.23x
Best for: income & stability and growth exposure
NRXP
NRx Pharmaceuticals, Inc.
The Long-Run Compounder
NRXP is the clearest fit if your priority is long-term compounding.
- -96.8% 10Y total return vs PSTV's -100.0%
- 101.1% revenue growth vs PSTV's -10.5%
- +58.9% vs PSTV's -52.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs PSTV's -10.5% |
| Quality / Margins | PSTV | -429.4% margin vs NRXP's -157.3% |
| Stability / Safety | PSTV | Beta 1.82 vs NRXP's 1.91 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NRXP | +58.9% vs PSTV's -52.0% |
| Efficiency (ROA) | PSTV | -156.0% ROA vs NRXP's -489.9% |
PSTV vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
FY 2025
PSTV vs NRXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPSTVLAGGINGNRXP
NRXPNRx Pharmaceuticals, …
1leads
PSTVPlus Therapeutics, In…
2leads
6 Total Categories
CATEGORYLEADERvs NRXPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PSTV5/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PSTV3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
NRXP6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PSTV leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
PSTV is the larger business by revenue, generating $5M annually — 21.5x NRXP's $242,000. PSTV is the more profitable business, keeping -4.3% of every revenue dollar as net income compared to NRXP's -157.3%.
| Metric | PSTVPlus Therapeutics… | NRXPNRx Pharmaceutica… |
|---|---|---|
| RevenueTrailing 12 months | $5M | $242,000 |
| EBITDAEarnings before interest/tax | -$15M | -$31M |
| Net IncomeAfter-tax profit | -$22M | -$38M |
| Free Cash FlowCash after capex | -$21M | -$12M |
| Gross MarginGross profit ÷ Revenue | +91.5% | +59.5% |
| Operating MarginEBIT ÷ Revenue | -2.9% | -63.0% |
| Net MarginNet income ÷ Revenue | -4.3% | -157.3% |
| FCF MarginFCF ÷ Revenue | -4.0% | -49.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +100.0% | -80.0% |
PSTV leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
Evenly matched — PSTV and NRXP each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | PSTVPlus Therapeutics… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Market CapShares × price | $15M | $84M |
| Enterprise ValueMkt cap + debt − cash | $7M | $77M |
| Trailing P/EPrice ÷ TTM EPS | -0.83x | -2.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 2.78x | 68.92x |
| Price / BookPrice ÷ Book value/share | 4.67x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — PSTV and NRXP each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PSTV leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs PSTV's 4/9, reflecting solid financial health.
| Metric | PSTVPlus Therapeutics… | NRXPNRx Pharmaceutica… |
|---|---|---|
| ROE (TTM)Return on equity | -5.6% | — |
| ROA (TTM)Return on assets | -156.0% | -4.9% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -3.8% | — |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.21x | — |
| Net DebtTotal debt minus cash | -$8M | -$7M |
| Cash & Equiv.Liquid assets | $9M | $8M |
| Total DebtShort + long-term debt | $821,000 | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | -4.07x | -24.18x |
PSTV leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
NRXP leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NRXP five years ago would be worth $99 today (with dividends reinvested), compared to $71 for PSTV. Over the past 12 months, NRXP leads with a +58.9% total return vs PSTV's -52.0%. The 3-year compound annual growth rate (CAGR) favors NRXP at -21.1% vs PSTV's -61.5% — a key indicator of consistent wealth creation.
| Metric | PSTVPlus Therapeutics… | NRXPNRx Pharmaceutica… |
|---|---|---|
| YTD ReturnYear-to-date | -56.8% | +16.4% |
| 1-Year ReturnPast 12 months | -52.0% | +58.9% |
| 3-Year ReturnCumulative with dividends | -94.3% | -50.8% |
| 5-Year ReturnCumulative with dividends | -99.3% | -99.0% |
| 10-Year ReturnCumulative with dividends | -100.0% | -96.8% |
| CAGR (3Y)Annualised 3-year return | -61.5% | -21.1% |
NRXP leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PSTV and NRXP each lead in 1 of 2 comparable metrics.
Risk & Volatility
PSTV is the less volatile stock with a 1.82 beta — it tends to amplify market swings less than NRXP's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 79.4% from its 52-week high vs PSTV's 25.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PSTVPlus Therapeutics… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.82x | 1.91x |
| 52-Week HighHighest price in past year | $23.43 | $3.84 |
| 52-Week LowLowest price in past year | $0.27 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +25.6% | +79.4% |
| RSI (14)Momentum oscillator 0–100 | 52.1 | 64.4 |
| Avg Volume (50D)Average daily shares traded | 365K | 914K |
Evenly matched — PSTV and NRXP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PSTVPlus Therapeutics… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PSTV leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NRXP leads in 1 (Total Returns). 2 tied.
Best OverallPlus Therapeutics, Inc. (PSTV)Leads 2 of 6 categories
Loading custom metrics...
PSTV vs NRXP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — PSTV or NRXP?
Over the past 5 years, NRx Pharmaceuticals, Inc.
(NRXP) delivered a total return of -99. 0%, compared to -99. 3% for Plus Therapeutics, Inc. (PSTV). Over 10 years, the gap is even starker: NRXP returned -96. 8% versus PSTV's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — PSTV or NRXP?
By beta (market sensitivity over 5 years), Plus Therapeutics, Inc.
(PSTV) is the lower-risk stock at 1. 82β versus NRx Pharmaceuticals, Inc. 's 1. 91β — meaning NRXP is approximately 5% more volatile than PSTV relative to the S&P 500.
03Which is growing faster — PSTV or NRXP?
On earnings-per-share growth, the picture is similar: Plus Therapeutics, Inc.
grew EPS 100. 0% year-over-year, compared to 43. 9% for NRx Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — PSTV or NRXP?
Plus Therapeutics, Inc.
(PSTV) is the more profitable company, earning -429. 4% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps -429. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PSTV leads at -293. 5% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — PSTV leads at 91. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — PSTV or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is PSTV or NRXP better for a retirement portfolio?
For long-horizon retirement investors, Plus Therapeutics, Inc.
(PSTV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PSTV: -100. 0%, NRXP: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between PSTV and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.